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The ubiquitin carboxyl-terminal esterase L1 gene, UCHL1, located on chromosome 4p14, has been studied as
a potential candidate gene for Parkinson’s disease risk. The authors conducted a Human Genome Epidemiology
review and meta-analysis of published case-control studies of the UCHL1 S18Y variant and Parkinson’s disease in
Asian and Caucasian samples. The meta-analysis of studies in populations of Asian ancestry showed a statistically
signiﬁcant associationbetween the Y allele and reduced riskof Parkinson’s disease under a recessivemodel (odds
ratio (OR) for YY vs. SY þ SS ¼ 0.79, 95% conﬁdence interval (CI): 0.67, 0.94; P ¼ 0.006). For a dominant model,
the association was not signiﬁcant in Asian populations (OR for YY þ SY vs. SS ¼ 0.88, 95% CI: 0.68, 1.14; P ¼
0.33). For populations of European ancestry, the meta-analysis showed a signiﬁcant association between the Y
allele and decreased risk of Parkinson’s disease under a dominant model (OR ¼ 0.89, 95% CI: 0.81, 0.98; P ¼
0.02) but not under a recessive model (OR ¼ 0.92, 95% CI: 0.66, 1.30; P ¼ 0.65). Using the Venice criteria,
developed by the Human Genome Epidemiology Network Working Group on the assessment of cumulative
evidence, the authors concluded that moderate evidence exists for an association between the S18Y variant
and Parkinson’s disease.
case-control studies; epidemiology; genes; genetics; meta-analysis; Parkinson disease; review; UCHL1
Abbreviations: CI, conﬁdence interval; OR, odds ratio; PARK, a region identiﬁed in linkage studies of Parkinson’s disease; SNP,
single nucleotide polymorphism; UCHL1, ubiquitin carboxyl-terminal esterase L1.
Editor’s note: This paper is also available on the website
of the Human Genome Epidemiology Network (http://
www.cdc.gov/genomics/hugenet/).
GENE
The ubiquitin carboxyl-terminal esterase L1 gene, UCHL1,
locatedonchromosome4(4p14),spans11.5kbandhas9exons
(Online Mendelian Inheritance in Man (OMIM); www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db¼OMIM)). UCHL1 protein
(OMIM #191342) expression is speciﬁc to neurons, cells of
the diffuse neuroendocrine system, testes, and ovaries (1, 2).
UCHL1proteinisespeciallyabundantinthebrain,constituting
1%–2% of soluble brain protein (3), and has been localized to
Lewybodiesandotherinclusionbodiescharacteristicofhuman
neurodegenerative diseases (4, 5).
The UCHL1 enzyme is involved in the ubiquitin protea-
some system, a cellular pathway responsible for the degra-
dation of misfolded and damaged proteins (6). The ubiquitin
proteasome system has been postulated to play an important
role in the etiology of Parkinson’s disease (for a review,
refer to Lim and Tan (7)). Speciﬁcally, UCHL1 is a member
of the ubiquitin C-terminal hydrolase family of deubiquiti-
nating enzymes, which catalyze the hydrolysis of polymeric
ubiquitin chains (8). In addition to a deubiquitination
function, in vitro studies have shown that UCHL1 has
dimerization-dependent ubiquitin ligase activity (9).
UCHL1-deﬁcient mice, known as gracile axonal dystrophy
mice, show neuronal loss in the spinal gracile tract and
exhibit early development sensory ataxia and progressive
1344 Am J Epidemiol 2009;170:1344–1357motor ataxia (10). In vitro studies of such mice show that
UCHL1 noncovalently bonds to ubiquitin, thereby prevent-
ing ubiquitin degradation and maintaining the cellular pool
of free ubiquitin (11). Posttranslational regulation, such as
monoubiquitination, is hypothesized to play an important
role in UCHL1 protein function (12).
UCHL1 has also been studied as a candidate gene for
Huntington’s disease (1, 13, 14) and Alzheimer’s disease
(3, 15), but evidence is not sufﬁcient to support or refute
an association. Additional studies have suggested that epi-
genetic changes altering UCHL1 gene and protein expres-
sion may also serve as a marker of disease status or
prognosis for several types of cancer (2, 16, 17).
GENE VARIANTS
Two variants in the UCHL1 gene have been examined in
association with Parkinson’s disease: I93M and S18Y (for
a previous review, refer to Healy et al. (1)). The I93M mis-
sense variant results from a cytosine-to-guanine transver-
sion in codon 93 of exon 4. This variant was originally
identiﬁed in 2 German siblings with familial Parkinson’s
disease (18). The affected subjects had a form of disease
that clinically resembled idiopathic Parkinson’s disease;
however, the father (a presumed carrier of the mutation)
did not display the Parkinson’s disease phenotype. In vitro
studies indicate that this mutation results in partial loss of
UCHL1 hydrolytic function (18, 19). The S18Y variant re-
sults from a cytosine-to-adenine transversion at codon 18 in
exon 3 (rs5030732). This variant was originally identiﬁed in
a study screening Parkinson’s disease patients for UCHL1
polymorphisms (20). In vitro studies provide evidence that
the S18Y mutation results in decreased ligase activity
and in slightly increased hydrolase activity compared with
wild-type UCHL1 (9, 19).
GENE VARIANT FREQUENCY
Several studies have speciﬁcally screened for the I93M
mutation in Parkinson’s disease subjects (21) and controls
(20, 22–24), including one relatively large sample of 229
German Parkinson’s disease patients (25). However, to date,
there has been no documented occurrence of the I93M
variant besides the 2 siblings in the original German
Parkinson’s disease family (1).
Our literature search did not identify any studies that have
conducted population-based surveys of S18Y frequency.
Therefore, we summarized allele frequency based on con-
trol samples from case-control studies. The frequency of the
Y allele varies across geographic regions (Table 1). The Y
allele frequency is higher among individuals of Asian de-
scent (46%–61%) than among those of European descent
(16%–24%). To date, no studies have been known to exam-
ine the frequency of the UCHL1 S18Y variant in other pop-
ulations, such as Africans, Southeast Asians, Native
Americans, Paciﬁc Islanders, or Australian Aboriginals.
Additional single nucleotide polymorphisms (SNPs) have
been characterized through resequencing and the HapMap
Project (http://hapmap.ncbi.nlm.nih.gov/abouthapmap.html).
Healy et al. (26) resequenced the UCHL1 gene in 64 unre-
lated white individuals, identifying 5 SNPs with minor allele
frequencies less than 5% and 23 SNPs with minor allele
frequencies greater than 5%. They used information on link-
age disequilibrium between these SNPs to determine that 3
SNPs were needed to tag common variation in the gene
(r
2 > 0.75) (26). We examined the current HapMap data
and found 10 SNPs with minor allele frequencies greater
than 5% in each of the 4 HapMap populations (Yoruba from
Ibadan, Nigeria; Japanese from Tokyo, Japan; Han Chinese
from Beijing, China; and Utah residents of northern and
western European ancestry) (27). Using tagSNP methods
based on pairwise linkage disequilibrium (r
2   0.80)
(28), we determined that 4 tagSNPs are needed to capture
commonvariants (minor allele frequencies greater than 5%)
for Utah residents of northern and western European ances-
try, Japanese from Tokyo, and Han Chinese from Beijing
and 5 tagSNPs for the Yoruba population from Ibadan.
Aside from the paper by Healy et al., none of the other
published studies have examined these variants in relation
to Parkinson’s disease.
The remainder of this review focuses on the S18Y variant
only, because it is the best studied of the 2 variants. Until
recently, the I93M variant had been identiﬁed in only 2
individuals, and a comprehensive tagSNP assessment of this
gene had been performed by only Healy et al. (26).
DISEASE
Clinical and pathologic characteristics
Parkinson’s disease is a progressive, neurodegenerative
disorder clinically deﬁned by a combination of cardinal mo-
tor features: tremor, rigidity, bradykinesia (slowness of
movement), and postural instability (29). The mainstay of
treatment for motor symptoms is dopamine replacement
therapy (e.g., levodopa), but current therapeutic strategies
are only palliative and do not substantially alter the under-
lying degenerative process. A number of nonmotor features
that are difﬁcult to treat are common in Parkinson’s disease,
including cognitive dysfunction, sleep disorders, psychosis,
depression, anosmia, and autonomic insufﬁciency (30).
Pathologically, Parkinson’s disease is characterized by a
profound loss of dopaminergicneurons within the substantia
nigra pars compacta and the presence of intraneuronal, cy-
toplasmic, eosinophilic inclusions called Lewy bodies (31).
Lewy bodies contain abnormal protein aggregates, and 2 of
the most abundant constituents are a-synuclein and ubiqui-
tin (32, 33). Parkinson’s disease becomes clinically evident
when approximately 80% of striatal dopamine and 50% of
nigral dopaminergic neurons are lost (34).
Most clinicians and researchers consider neuropathologic
diagnosis to be the ‘‘gold standard’’ for Parkinson’s disease.
Clinicopathologic series indicate that diagnostic accuracy
based on clinical ﬁndings alone ranges from 75.6% to
98.6% (35–39). Accuracy is highest when the diagnosis is
made by a movement disorder specialist and is based on
longitudinal assessments (36). The clinical diagnostic criteria
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Kingdom Parkinson’s Disease Society Brain Bank (40).
Parkinson’s disease prevalence
Parkinson’s disease is the second most common neurode-
generative disease worldwide, after Alzheimer’s disease.
Parkinson’s disease prevalence increases with age, so its
burden is expected to increase with the aging US population
(41).Prevalence of Parkinson’s disease is higher in men than
in women (42–44), although this ﬁnding is not observed in
all studies. This gender difference is hypothesized to result
from hormonal differences or differences in exposure to
environmental risk factors (45).
Studies of Parkinson’s disease prevalence and incidence
have been conducted in various populations worldwide (41,
45–48). Data suggest that prevalence and incidence are sim-
ilar across European and Asian populations. Even after
accountingfordifferencesinagestructure,prevalenceislower
in Africa than in Europe and Asia (48, 49). However, studies
have differed in terms of case deﬁnitions, methods of case
ascertainment, and age categories examined. Therefore,
these trends may simply reﬂect methodological differences
between studies (45, 50).
Genetic risk factors
Parkinson’s disease is hypothesized to be a complex dis-
ease, with genetic and environmental contributions to its
etiology. Evidence for genetic factors in Parkinson’s disease
was ﬁrst mentioned in 1902, whenWilliamGowers,a British
neurologist, noted that approximately 15% of his Parkinson’s
disease patients reported an affected family member (51).
Although the genetic basis for Parkinson’s disease is some-
times debated (52), and results from twin studies are incon-
sistent (53, 54), a large number of recent case-control studies
have demonstrated that, compared with controls, Parkinson’s
disease subjects are 2–14 times more likely to report a family
history of the disease (55).
Further evidence for the genetic basis of Parkinson’s dis-
ease comes from the identiﬁcation of causal genes in fam-
ilies in which Parkinson’s disease is inherited as a simple
Mendelian disorder, either in an autosomal dominant or an
autosomal recessive pattern (for recent reviews, refer to Tan
Table 1. Worldwide Frequency of the UCHL1 Y Allele
Geographic Region and
Study (Reference No.) Country Ethnic
Group No. Allele
Frequency
95% Conﬁdence
Interval
a
Asia
Wang et al., 2002 (98) China Asian 160 0.47 0.41, 0.53
Mizuta et al., 2006 (106) Japan Asian 736 0.49 0.47, 0.50
Momose et al., 2002 (107) Japan Asian 248 0.49 0.45, 0.53
Satoh and Kuroda, 2001 (23) Japan Asian 155 0.54 0.49, 0.59
Zhang et al., 2000 (108) Japan Asian 160 0.61
b 0.56, 0.67
Tan et al., 2006 (109) Singapore Asian 341 0.46
b 0.42, 0.50
Australia
Mellick and Silburn, 2000 (100) Australia Caucasian 142 0.16 0.11, 0.20
Europe
Elbaz et al., 2003 (97) France Caucasian 488 0.19
b 0.17, 0.22
Levecque et al., 2001 (101) France Caucasian 93 0.18 0.13, 0.24
Wintermeyer et al., 2000 (25) Germany Caucasian 200 0.20 0.16, 0.24
Savettieri et al., 2001 (102) Italy Caucasian 165 0.17 0.13, 0.21
Carmine Belin et al., 2007
c (99) Sweden Caucasian 285 0.17 0.14, 0.20
Healy et al., 2006 (26) United Kingdom Caucasian 1,482 0.17
b 0.15, 0.18
North America
Facheris et al., 2005 (92) United States Caucasian 497 0.19
b 0.16, 0.21
Hutter et al., 2008 (95) United States Caucasian 2,016 0.19 0.18, 0.20
Maraganore et al., 1999 (20) United States Caucasian 110 0.23 0.18, 0.29
Maraganore et al., 2004
d (91) United States Caucasian 80 0.24 0.17, 0.31
Zhang et al., 2000 (108) United States Caucasian 142 0.19
b 0.14, 0.25
Abbreviation: UCHL1, ubiquitin carboxyl-terminal esterase L1 gene.
a Calculated by using exact conﬁdence intervals.
b Allele frequencies were calculated from genotype frequencies in controls.
c Incorrect frequency was presented in the initial publication; corrected frequency was obtained courtesy of the
study author.
d Excluding cases included in genotype counts in Maraganore et al. (20).
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Westerlund (58), and Lesage and Brice (59)). Table 2 pro-
vides details of regions identiﬁed as causal for monogenetic
forms of Parkinson’s disease. Mutations in these genes typ-
ically follow Mendelian patterns of inheritance within
families. In some cases, the mutations result in disorders
with clinical and/or pathologic distinctions from classic
Parkinson’s disease, most notably several monogenetic
forms of the disease with an earlier age at onset.
Traditionally, regions identiﬁed in linkage studies of
Parkinson’s disease are initially given the designation
PARK# (e.g., PARK1, PARK2, PARK3). Autosomal dom-
inant forms of Parkinson’s disease have been associated
with mutations in the a-synuclein gene (SNCA)( P A R K 1
and PARK4 locus, chromosomal region 4q21) (60) and
the leucine-rich repeat kinase-2 gene (LRRK2)( P A R K 8
locus, 12p11.2–q13.1) (61,62).Autosomal recessiveforms
have been associated with mutations in the parkin gene
(PARK2, 6q25–27) (63), oncogene DJ1 (DJ-1)( P A R K 7 ,
1p36) (64), the PTEN-induced putative kinase 1 gene
(PINK1) (PARK6, 1p36) (65), and the ATPase type 13A2
gene (ATP13A2) (PARK9, 1p36) (66). Additional regions
have been identiﬁed through linkage studies, including the
PARK3 (2p13) (67), PARK10 (1p32) (68, 69), and
PARK11 (2q36–q37) (70) regions. Speciﬁc causal genes
have yet to be identiﬁed in these latter regions, and char-
acterization of candidate genes remains an active area
of research. For example, recent studies have nominated
the sepiapterin reductase gene (SPR) as the most likely
candidate in the PARK3 region (71). The discovery of
these causal mutations has provided important insights
into biochemical pathways involved in the etiology of
Parkinson’s disease.
In addition, association studies have examined several
other potential Parkinson’s disease susceptibility genes
identiﬁed on the basis of their function or by their role in
other neurodegenerative diseases (72). The PDGene website
(www.pdgene.org), funded primarily by The Michael J. Fox
Foundation for Parkinson’s Research and the Alzheimer Re-
search Forum, provides summaries of results from genetic
epidemiologic studies of Parkinson’s disease. More than
250 proposed Parkinson’s disease susceptibility genes have
been evaluated, and a number of potential pathways under-
lying Parkinson’s disease etiology have been implicated,
including those involved in mitochondrial stress, the ubiq-
uitin proteasome system, and axon guidance. Of the genes
summarized on PDGene, the strongest, most consistently
replicated associations are seen for GBA (glucosidase, beta,
acid), LRRK2, SNCA, and MAPT (microtubule-associated
protein tau). More recently, additional candidate genes have
been proposed based on the results of 3 genome-wide asso-
ciation studies (73–75) and a genome-wide meta-analysis of
2 of these studies (76). The results from the initial 2
genome-wide association studies have not been consistently
replicated(77–80).Themostrecentgenome-wideassociation
study focused on familial Parkinson’s disease and supported
associations for MAPT and SNCA as well as identifying a
potential new susceptibility region near GAK/DGKQ
Table 2. PARK Regions That Have Been Linked to Parkinson’s Disease in Family-based
Studies
Locus Gene in Region Linked
to Parkinson’s Disease
Chromosomal
Location
Form of Parkinson’s
Disease
PARK1 SNCA 4q21 Autosomal dominant
PARK2 PRKN 6q25.2–q27 Autosomal recessive
(juvenile onset)
PARK3 —
a 2p13 Autosomal dominant
PARK4 SNCA 4p21 Autosomal dominant
PARK5 — 4p14 Autosomal dominant
and sporadic
PARK6 PINK1 1p36 Autosomal recessive
PARK7 DJ-1 1p36 Autosomal recessive
and early onset
PARK8 LRRK2 12q12 Autosomal dominant
and sporadic
PARK9 ATP13A2 1p36 Early onset
PARK10 — 1p32 Idiopathic
PARK11 — 2q36–q37 Autosomal dominant
and sporadic
PARK12 — X Familial (mode of inheritance
not known)
PARK13 HTRA2 2p13 Idiopathic
Abbreviations: ATP13A2, ATPase type 13A2 gene; DJ-1, oncogene DJ1; HTRA2, HtrA serine
peptidase 2 gene; LRRK2, leucine-rich repeat kinase-2 gene; PARK, a region identiﬁed in linkage
studies of Parkinson’s disease; PINK1, PTEN-induced putative kinase 1 gene; PRKN, Parkin-
son’s disease gene; SNCA, a-synuclein gene.
a —, not known.
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chromosome 4 (4, 75).
Environmental risk factors
A number of environmental exposures have been evalu-
ated as risk factors for the development of Parkinson’s dis-
ease (45, 81), with the most commonly studied being
smoking, caffeine or coffee consumption, alcohol consump-
tion, and use of nonsteroidal antiinﬂammatory drugs. Each
of these exposures has been shown to be associated with
a decreased risk of Parkinson’s disease, and the smoking
association has been the most consistently replicated (45,
82, 83). To date, there is no evidence for 2-way or 3-way
Table 3. Genotype Counts From Case-Control Studies Evaluating the Association Between the UCHL1 S18Y
Variant and Parkinson’s Disease Published Through July 1, 2008
Country and Study
(Reference No.) Genotype No. of
Cases
No. of
Controls
Recalculated
Odds Ratio
a
95% Conﬁdence
Interval P Value
Asia
China
Wang et al., 2002 (98) SS 40 45 1.00 0.802
SY 82 80 1.15 0.66, 2.02
YY 38 35 1.22 0.62, 2.4
Japan
Mizuta et al., 2006
b (106) SS 149 199 1.00 0.165
SY 340 366 1.22 0.94, 1.59
YY 124 171 1.00 0.72, 1.37
Momose et al., 2002 (107) SS 71 61 1.00 0.136
SY 119 122 0.84 0.54, 1.31
YY 40 65 0.53 0.30, 0.92
Satoh and Kuroda, 2001 (23) SS 28 41 1.00 0.011
SY 35 62 0.83 0.42, 1.64
YY 11 52 0.31 0.12, 0.74
Zhang et al., 2000 (108) SS 52 35 1.00 0.095
SY 77 86 0.60 0.34, 1.05
YY 31 39 0.54 0.27, 1.06
Singapore
Tan et al., 2006 (109) SS 93 71 1.00 0.202
SY 194 172 0.86 0.58, 1.27
YY 88 98 0.69 0.44, 1.07
Australia
Australia
Mellick and Silburn, 2000 (100) SS 100 101 1.00 0.188
SY 33 38 0.88 0.49, 1.56
YY 9 3 3.03 0.72, 17.81
Europe
France
Elbaz et al., 2003 (97) SS 139 323 1.00 0.182
SY 67 145 1.07 0.74, 1.55
YY 3 20 0.35 0.07, 1.21
Levecque et al., 2001 (101) SS 76 64 1.00 0.852
SY 33 24 1.16 0.59, 2.27
YY 5
c 5 0.84 0.19, 3.84
Germany
Wintermeyer et al., 2000 (25) SS 169 128 1.00 0.059
SY 51 65 0.59 0.38, 0.94
YY 9 7 0.97 0.31, 3.17
Table continues
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of over-the-counter nonsteroidal antiinﬂammatory drugs
(83). The effects are instead thought to be independent
and cumulative, although evidence is limited (83, 84).
Case-control studies have also examined exposures re-
lated to living in a rural setting, including the use of well
water, farming, and pesticide exposure. The limited evi-
dence available suggests a more than 2-fold increased risk
of Parkinson’s disease associated with pesticide exposure
and a weaker association with well-water exposure, farming
as an occupation, and generally living in a rural setting (82,
85–88).
Other environmental risk factors possibly associated with
Parkinson’s disease include educational status, occupation,
body mass index, dairy product consumption, and estrogen
exposure, although results have been inconsistent. Higher
levels of education have been shown to be associated with
increased risk of Parkinson’s disease, and physicians have
been found to have higher rates of Parkinson’s disease than
nonphysicians (89). Construction workers, miners, produc-
tion workers, metal workers, and engineers have lower rates
of Parkinson’s disease than people in other occupations (89).
In addition, Parkinson’s disease is typically less common
in women than in men (42). Evidence from animal models,
Table 3. Continued
Country and Study
(Reference No.) Genotype No. of
Cases
No. of
Controls
Recalculated
Odds Ratio
a
95% Conﬁdence
Interval P Value
Italy
Savettieri et al., 2001 (102) SS 118 115 1.00 0.999
SY 46 45 1.00 0.60, 1.67
YY 5 5 0.97 0.22, 4.36
Sweden
Carmine Belin et al., 2007
d (99) SS 218 191 1.00 0.216
SY 74 89 0.73 0.50, 1.07
YY 4 5 0.70 0.14, 3.31
United Kingdom
Healy et al., 2006 (26) SS 1,074 1,028 1.00 0.54
SY 409 418 0.94 0.79, 1.1
YY 44 36 1.17 0.73, 1.89
North America
United States
Facheris et al., 2005 (92) SS 44 41 1.00 0.044
SY 26 23 1.05 0.49, 2.26
YY 0 6 0 0, 0.62
Hutter et al., 2008 (95) SS 1,191 1,324 1.00 0.388
SY 509 621 0.91 0.79, 1.95
YY 57 71 0.89 0.61, 1.29
Maraganore et al., 1999
c (20) SS 95 64 1.00 0.068
SY 35 42 0.56 0.31, 1.01
YY 2 4 0.34 0.03, 2.45
Maraganore et al., 2004
e (91) SS 120 48 1.00
SY 48 25 0.77 0.41, 1.45
YY 7 7 0.4 0.11, 1.42
Zhang et al., 2000 (108) SS 108 105 1.00 0.285
SY 40 36 1.08 0.62, 1.89
YY 5 1 4.86 0.53, 232.03
Abbreviation: UCHL1, ubiquitin carboxyl-terminal esterase L1 gene.
a Unadjusted odds ratios were calculated by the authors of the present review using raw genotype data presented
in published studies.
b Excluding cases included in genotype counts in the Momose et al. study (107).
c Incorrect count presented in the initial publication; corrected genotype count obtained from Maraganore et al.
(91).
d Incorrect counts presented in the initial publication; corrected genotype counts obtained courtesy of the author.
e Excluding cases included in genotype counts in the Maraganore et al. study (20).
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tect the nigrostriatal dopaminergic pathway affected in
Parkinson’s disease (90). Additional studies with large sam-
ple sizes must be completed to establish the role of these
exposures in Parkinson’s disease development.
ASSOCIATIONS
Studies were selected through a computerized search of
PubMed and the Web of Science by using the keywords
‘‘Parkinson disease,’’ ‘‘Parkinson’s disease,’’ ‘‘Parkinsons
disease,’’ ‘‘PD,’’ ‘‘UCHL1,’’ ‘‘UCH-L1,’’ and ‘‘UCHL-1.’’
We included papers published through July 1, 2008. Refer-
ences in the papers found via the computerized search were
examined to identify additional studies. Studies were in-
cluded if they provided original data on the association of
Parkinson’s disease with UCHL1, were published in peer-
reviewed journals, and used either a case-control or a
family-based design. Two of the authors (M. R. and C. H.)
independently performed this search, reviewed all studies,
and abstracted data using a standardized form.
Some papers contained discrepancies between the sample
sizes and the genotype/allele counts presented. When dis-
crepancies were found, we either referred to updated data in
existing meta-analyses (26, 91) or contacted the correspond-
ing author to resolve the discrepancy. To date, studies of the
S18Y variant and Parkinson’s disease have been performed
exclusively in populations of European or Asian descent.
One study was primarily family based (92), whereas the
remainder used case-control designs. For the study that
was both family based and case-control, we present only
the case-control results in our tables and meta-analysis. In
addition to ethnic group differences, other important differ-
ences between studies were the control selection methods
and the covariates used as adjustment factors in the analysis.
Most studies adjusted for covariates, including age and sex,
and covariates included in the model do not appear to ac-
count for differences in results.
We conducted a meta-analysis to evaluate the relation be-
tween UCHL1 S18Y and Parkinson’s disease. Because of
allele frequency differences between ethnic groups and
potential population stratiﬁcation, we performed the meta-
analysis separately for studies of subjects of European ances-
try (11 studies) and Asian ancestry (5 studies). Currently,
there is no conclusive evidence for the genetic model under-
lying the potential relation between S18Y genotype and
Parkinson’s disease; therefore, we examined a dominant, re-
cessive, and additive model of inheritance for the minor (Y)
allele. The overall odds ratio, 95% conﬁdence interval, and
P value were calculated by using a random-effects model
(93). The random-effects (DerSimonian-Laird) model ac-
counts for between-study heterogeneity. Forest plots were
used to display the results from individual studies, as well
as summary results. The signiﬁcance of between-study het-
erogeneity was evaluated by using Cochran’s Q statistic. If
the P value was less than 0.10, the heterogeneity was consid-
ered statistically signiﬁcant. We also quantiﬁed heterogeneity
using the I
2 metric (94). I
2 takes values between 0% and
100%; higher values indicate higher levels of heterogeneity.
Pearson’s v
2 was used to evaluate Hardy-Weinberg equi-
librium in the control group for all studies. Samples with P
values below 0.05 were considered out of Hardy-Weinberg
disequilibrium and were excluded from the meta-analysis.
One study (Satoh and Kuroda (23)) was out of Hardy-
Weinberg equilibrium in the control group (P ¼ 0.01) and
was excluded from the primary meta-analysis. For sensitiv-
ity analysis, we repeated the meta-analysis including the
Satoh and Kuroda study. We also repeated the analysis
excluding the subset of the Maraganore et al. study (20)
included in their initial 1999 report and excluding the study
by Facheris et al. (92) because it was primarily family based.
All analyses were performed by using Stata software,
version 9.0 (Stata Corporation, College Station, Texas).
RESULTS
Table 3 summarizes the evidence for an association
between UCHL1 S18Y and Parkinson’s disease from 6
case-control studies of subjects of Asian ancestry and 12
case-control studies of subjects of European ancestry. The
table includes genotype counts, a summary of the primary
ﬁndingasreportedintheoriginalpublication,andacalculation
ofthecrudeoddsratiosforthecomparisonofSYversusSSand
YY versus SS. Although the results are not completely consis-
tent across studies, the overall results show little evidence for
anassociationwiththeS18Yvariant.Withtheexceptionofthe
2 recent studies by Healy et al. (26) (1,536 cases and 1,487
controls) and Hutter et al. (95) (1,757 cases and 2,016 con-
trols), the sample sizes for these studies were relatively small
(median sample size: 169 cases and 165 controls).
Figure 1 shows the results of the meta-analysis for pop-
ulations reported to be of Asian ancestry. The overall odds
ratio under a dominant model was not signiﬁcantly differ-
ent from 1 (odds ratio (OR) ¼ 0.88, 95% conﬁdence in-
terval (CI): 0.68, 1.14; P ¼ 0.33); however, there was
evidence for a signiﬁcant association under a recessive
model (OR ¼ 0.79, 95% CI: 0.67, 0.94; P ¼ 0.01). Includ-
ing the one study in which allele frequencies were not in
Hardy-Weinberg equilibrium (23) did not substantively
change the results. There was marginal evidence for be-
tween-study heterogeneity under the dominant model (P ¼
0.044; I
2 ¼ 56.0%) but not under the recessive model (P ¼
0.463; I
2 ¼ 0.0%). The odds ratio for meta-analysis under
a random-effects, additive model (coding genotypes 0, 1, 2
based on numbers of copies of the Y allele) was signiﬁcant
for populations of Asian descent (OR ¼ 0.83, 95% CI: 0.71,
0.99; P ¼ 0.029; I
2 ¼ 59.9%; heterogeneity P ¼ 0.029).
When we excluded the study out of Hardy-Weinberg equi-
librium (Satoh and Kuroda (23)), the odds ratio for meta-
analysis under a random-effects, additive model suggested
a trend toward reduced risk for populations of Asian de-
scent, although it was not statistically signiﬁcant (OR ¼
0.87, 95% CI: 0.75, 1.02; P ¼ 0.080; I
2¼ 50.2%; heteroge-
neity P ¼ 0.090).
Figure 2 shows the results of the meta-analysis for sub-
jects of European ancestry. In contrast to the results in Asian
samples, the overall odds ratio under a dominant model was
signiﬁcantly different from 1 (OR ¼ 0.89, 95% CI: 0.81,
0.98; P ¼ 0.02); however, the odds ratio was not signiﬁcant
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Am J Epidemiol 2009;170:1344–1357underarecessivemodel(OR¼0.92,95%CI:0.66,1.30;P¼
0.65). Excluding data from the ﬁrst study published (20) or
from the family-based study (92) did not substantively
change the results of the analysis. There was no signiﬁcant
evidence for heterogeneity between studies (P ¼ 0.355,
I
2 ¼ 11.0% for the dominant model; P ¼ 0.154, I
2 ¼ 25.1%
for the recessive model). The odds ratio for meta-analysis
under a random-effects, additive model (coding genotypes 0,
1,2basedonnumbersofcopiesoftheYallele)wassigniﬁcant
inpopulationsofEuropeandescent(OR¼0.90,95%CI:0.82,
0.99; P ¼ 0.035; I
2¼ 21.9%; heterogeneity P ¼ 0.23).
Two studies previously performed analyses to summarize
the association between the UCHL1 S18Y variant and
Parkinson’s disease across studies. The ﬁrst was a pooled
analysis by Maraganore et al. (91), combining data from 11
studies with subjects of both European and Asian descent,
including an unpublished abstract not used in our review
(96). The authors of this pooled analysis concluded that
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Figure 1. Meta-analysis of published Parkinson’s disease–UCHL1 S18Y case-control association studies of individuals of Asian ancestry: A)
dominant and B) recessive model of inheritance. For each study (ordered by publication year), the odds ratio (OR) and 95% conﬁdence interval (CI)
for Parkinson’s disease comparing the referent group to the risk group are shown. The overall odds ratio (dotted line and diamond) and 95%
conﬁdence interval (calculated under a random-effects model) are also shown. The referent group under the dominant model comprises the SS
homozygotes, and the referent group under the recessive model comprises the SS homozygotes and SY heterozygotes. The size of each box,
representing each odds ratio estimate, reﬂects the sample size of the study relative to the other studies. UCHL1, ubiquitin carboxyl-terminal
esterase L1 gene.
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at reduced risk of Parkinson’s disease (meta-analysis
OR under a dominant model comparing Y/Y þ Y/S vs.
S/S ¼ 0.84, 95% CI: 0.73, 0.95). The second was a meta-
analysis by Healy etal. (26) that examined8studies of white
subjects and concluded that UCHL1 is not a susceptibility
gene (meta-analysis under a dominant model OR ¼ 0.96,
95% CI: 0.86, 1.08).
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Figure 2. Meta-analysis of published Parkinson’s disease–UCHL1 S18Y case-control association studies of individuals of European ancestry:
A) dominant and B) recessive model of inheritance. For each study (ordered by publication year), the odds ratio (OR) and 95% conﬁdence interval
(CI) for Parkinson’s disease comparing the referent group to the risk group are shown. The overall odds ratio (dotted line and diamond) and 95%
conﬁdence interval (calculated under a random-effects model) are also shown. The referent group under the dominant model comprises the SS
homozygotes, and the referent group under the recessive model comprises the SS homozygotes and SY heterozygotes. The size of each box,
representing each odds ratio estimate, reﬂects the sample size of the study relative to the other studies. Complete data from Maraganore et al. (91)
are presented (including data from Maraganore et al. (20) and additional data included in Maraganore et al. (91)). UCHL1, ubiquitin carboxyl-
terminal esterase L1 gene.
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the ethnic groups studied. Maraganore et al. (91) included
all studies, whereas Healy et al. (26) restricted their meta-
analysis to white populations. Indeed, in the Maraganore
et al. study, the meta-analysis results were not signiﬁcant
when restricted to white populations. Our results are consis-
tent with these ﬁndings, in that we found slight differences
in the meta-analysis results for populations of Asian descent
compared with populations of European descent. Notably,
the association was signiﬁcant under a recessive model in
Asian populations but under a dominant model in popula-
tions of European descent. This ﬁnding may reﬂect under-
lying biologic differences or simply the differences in allele
frequencies. There is more power to detect a recessive as-
sociation in populations of Asian descent, because the minor
allele frequency is higher.
INTERACTIONS
Most association studies of the UCHL1 S18Y variant and
Parkinson’s disease have focused on main effects between
S18Yand case-control status. However, a number of studies
have also examined potential effect modiﬁcation by age.
More speciﬁcally, 4 studies found evidence for an associa-
tion when restricting the analysis to early-onset cases (20,
97–99), but 3 studies did not (1, 95, 100). A major difﬁculty
when comparing results across studies is the difference in
the age cutoff used to deﬁne early onset. The most common
was 50 years (1, 95, 98–101), but cutoff points of 59 years
(102) and 67 years (91) were also used. Further studies
differ as to whether cases were stratiﬁed by age at onset,
age at diagnosis, or age at study entry and whether controls
were also stratiﬁed by age. These inconsistencies limit our
ability to perform a rigorous meta-analysis stratiﬁed by age.
To date, 3 studies have examined gene-gene and/or gene-
environment interactions involving UCHL1 and Parkinson’s
disease. Elbaz et al. (97) examined potential interactions of
the UCHL1 S18Y variant with smoking and pesticide use;
they did not observe a main effect for the S18Y variant, and
there was no evidence for an interaction with either of these
environmental exposures. Maraganore et al. (103) reported
evidence for gene-gene interaction between UCHL1 and
a-synuclein genotypes in women, although they did not ﬁnd
an interaction in men. A third study by McCulloch et al. (84)
examined UCHL1 S18Y in conjunction with 3 other candi-
date gene polymorphisms (SNCA Rep1, MAPT H1/H2 hap-
lotypes, and apolipoprotein E (APOE) e2/e3/e4) and 2
environmental factors (smoking and caffeinated coffee con-
sumption). The authors did not observe evidence for a main
effect with UCHL1 S18Yor for interactions with smoking or
caffeinated coffee consumption. However, they did report
evidence for gene-environment interactions for polymor-
phisms in APOE and coffee as well as for SNCA and smok-
ing (84).
LABORATORY AND POPULATION TESTS
UCHL1 genotyping is performed routinely in research
settings; however, a UCHL1 laboratory test is not commer-
cially available at this time. Given the lack of conclusive
evidence supporting a strong association between UCHL1
polymorphisms and Parkinson’s disease, it seems unlikely
that UCHL1 population testing will be undertaken in the
near future.
OTHER PUBLIC HEALTH APPLICATIONS
The Venice criteria were developed by the Human Ge-
nome Epidemiology Network (HuGENet) Working Group
to provide guidance in assessing the cumulative epidemio-
logic evidence of genetic association studies (104). Brieﬂy,
Ioannidis et al. (104) suggest that 3 areas be considered
when assessing the published literature: amount of evi-
dence, replication, and protection from bias. The evidence
in each of these areas is scored as either A, B, or C and is
used in combination to provide an overall assessment of the
credibility of the association between thegenetic variant and
phenotype in question. Evidence meeting the highest stan-
dards are given a score of A (more than 1,000 total subjects
in the least common genotype group; extensive replication
with good consistency between studies; little to no obvious
bias in estimates for amount of evidence, replication, and
protection from bias), whereas meeting moderate criteria
receives a score of B (e.g., 100–1,000 total subjects in the
least common genotype group; replication, but moderate
inconsistency between studies; missing information to as-
sess bias), and those of lowest quality receive a score of C.
These criteria were applied as follows to evaluate the overall
evidence for an association between the UCHL1 S18Y
variant and Parkinson’s disease.
First, we considered the amount of evidence. In Asian
samples, our meta-analysis showed a signiﬁcantly reduced
risk of Parkinson’s disease for the Y variant under a reces-
sive model but not under a dominant model. In populations
of European descent, our meta-analysis found a signiﬁ-
cantlyreducedriskofParkinson’sdiseaseunderadominant
model but not a recessive model. The frequency of the Y
allele ranges from 47% to 61% in samples from Asian
countries and from 16% to 22% in populations of European
origin, and the total sample size in our meta-analysis was
13,398 cases and controls (3,412 Asian, 9,986 European).
Therefore, the amount of evidence supporting the associ-
ation exceeds the n (minor allele) ¼ 1,000 needed to
qualify as ‘‘large-scale evidence’’ (category A). Second,
we considered the level of replication. We observed only
minimal between-study heterogeneity in our meta-analysis;
however, the total number of studies examining the as-
sociation of UCHL1 S18Y with Parkinson’s disease in
each ethnic group was relatively small. Therefore, we
consider the credibility based on replication to be part of
category B.
Finally, we considered the potential for bias. There was no
obvious bias that may have affected the UCHL1–Parkinson’s
disease association, but, as is true for many candidate gene
studies, most studies did not publish sufﬁcient information to
fully evaluate the potential for bias (16). Bias is a particularly
important issue regarding the association between UCHL1
S18Y and Parkinson’s disease given the relatively small
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the entire association. Thus, we assign a score of B for pro-
tection from bias. The overall score using the Venice criteria
is therefore ‘‘ABB,’’ consistent with moderate evidence sup-
portingtheassociationbetweenUCHL1S18YandParkinson’s
disease.
Given the moderate degree of evidence for UCHL1 as
a Parkinson’s disease susceptibility gene, and the lack of
effective prevention measures for Parkinson’s disease, there
is no current public health application for this association.
This situation might change in the future if neuroprotective
therapies are developed that, if started earlier, could delay
disease onset. Finally, it is also possible that interactions
between genetic variants and pharmacologic agents will
be identiﬁed such that genotypes for UCHL1 or other sus-
ceptibility genes might prove useful in tailoring a patient’s
medication regimen.
CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE RESEARCH
In summary, the evidence for the S18Y variant of
UCHL1 as a Parkinson’s disease susceptibility factor is
moderate and suggests an effect size of 0.79–0.92. This
effect size is similar to the magnitude of effect sizes re-
ported by other genome-wide association studies of com-
plex disease (76) and for replication of candidate genes
(103). Two previous meta-analyses have been published
on this subject. We added 2 studies in Asian populations
and 2 studies in populations of European descent not in-
cluded in the previous meta-analyses. Consistent with
Maraganore et al. (91), we found a signiﬁcant result under
a recessive model but not a dominant model in Asian pop-
ulations. Our paper is the ﬁrst known to show a signiﬁcant
association in a meta-
analysis of populations of European descent, although both
previous meta-analyses found a nonsigniﬁcant trend to-
ward an association in a dominant model (26, 91). It is
possible that our study is the ﬁrst adequately powered to
detect a signiﬁcant association given the moderate effect
size and the lower allele frequency in European
populations.
Additional large, well-designed studies in Asian populations
and in other ethnic groups are needed to determine whether
these effects are consistent across groups. Ideally, these studies
w o u l dh a v ea d e q u a t es a m p l es i z es and detailed/standardized
phenotypic information to comprehensively evaluate gene-
gene and gene-environment interactions. Such studies would
beneﬁt from using a tagSNP approach to comprehensively
examinevariation across the UCHL1 gene rather than focusing
solely on the S18Y variant.
Additional research focusing on the molecular biology of
UCHL1 function and Parkinson’s disease is also needed. In
particular, studies should attempt to better elucidate the role
of UCHL1 in neuronal function and the role of the ubiquitin
proteasome system in Parkinson’s disease pathogenesis
(105). Combining human genetic studies and functional
analyses may provide new insights that could ultimately
translate into more effective prevention and treatment op-
tions for Parkinson’s disease.
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